NewsDialy
Three international lawsuits hinge on a single category of intellectual property: patents covering lipid nanoparticle technology.
A lipid nanoparticle, or LNP, is the fatty envelope that encases and delivers genetic material into cells.
Arbutus Biopharma and Genevant, its exclusive licensee, filed the suits claiming that Pfizer and BioNTech used their protected LNP technology without authorization.
In the same announcement, Arbutus said it received its first payment under an existing settlement with Moderna and plans to return capital to shareholders.
Keep reading